Patents Assigned to Quest Diagnostics Investments Incorporated
  • PROGNOSTIC ASSAYS FOR MAINTENANCE HEMODIALYSIS PATIENTS
    Publication number: 20170343568
    Abstract: Described herein are methods for determining the overall survival of maintenance hemodialysis patients. The methods include measuring low density lipoprotein (LDL) particle size and subfraction concentrations as prognostic tools for early mortality risk detection. For example, the presence of increased very small LDL concentration or decreased LDL particle size in blood-serum serves as a useful means for prognostic risk assessment and monitoring.
    Type: Application
    Filed: April 7, 2017
    Publication date: November 30, 2017
    Applicants: Quest Diagnostics Investments Incorporated, Los Angeles Biomedical Research Institute
    Inventors: Kamyar Kalantar-Zadeh, Michael P. Caulfield, Wael A. Salameh
  • DIAGNOSIS OF PROSTATE CANCER
    Publication number: 20170342402
    Abstract: The invention provides methods for isolating RNA from whole urine and urine fractions for the diagnosis of prostate cancer and/or benign prostate hyperplasia. An exemplary method for diagnosing prostate cancer in an individual, said method comprises: (a) determining the amount of RNA encoding one or more diagnostic genes in the soluble urine fraction of a urine sample obtained from said individual; (b) comparing the amount of said RNA to a reference value for said one or more diagnostic genes, wherein said reference value is derived from the amount of RNA encoding said one or more diagnostic genes in one or more individuals that do not have prostate cancer; and (c) diagnosing said individual as having prostate cancer when the amount of said RNA is greater than said reference value.
    Type: Application
    Filed: May 12, 2017
    Publication date: November 30, 2017
    Applicant: Quest Diagnostics Investments Incorporated
    Inventor: Heather R. Sanders
  • GRAPHICAL PRESENTATION OF MEDICAL DATA
    Publication number: 20170337331
    Abstract: Methods and user interfaces are provided for the display of data comprising series of data over time, with particular application to medical laboratory results and prescriptions of medication. A user may view multiple results simultaneously in a single display, with the abilities to zoom the time scale in and out and to select the time period for which results are displayed. Multiple displayed items of data may be selected for simultaneous display along a common time axis in a zoomable graph, facilitating interpretation of relationships between and/or among data items.
    Type: Application
    Filed: August 10, 2017
    Publication date: November 23, 2017
    Applicant: QUEST DIAGNOSTICS INVESTMENTS INCORPORATED
    Inventor: Kavya Ramachandran
  • APTAMERS AND DIAGNOSTIC METHODS FOR DETECTING THE EGF RECEPTOR
    Publication number: 20170328909
    Abstract: The present invention provides aptamers that specifically bind to the EGF receptor in a sample, and diagnostic and analytical methods using those aptamers. In some embodiments, the aptamers include a 3? cap. In some embodiments, the 3? cap is an inverted deoxythymidine. In some embodiments the aptamers include a spacer and at least one moiety selected from the group consisting of binding pair member and a detectable label, wherein the spacer is attached to the 5?-end of the aptamer and the moiety is attached the 5? end of the spacer. In some embodiments the spacer is hexaethylene glycol. In some embodiments, the binding pair member biotin. In some embodiments the detectable label is a fluorophore.
    Type: Application
    Filed: May 5, 2017
    Publication date: November 16, 2017
    Applicants: Quest Diagnostics Investments Incorporated, SOMALOGIC, INC.
    Inventors: Chris Bock, Deborah Ayers, Malti P. Nikrad, Bharat Nathu Gawande, Jennifer C. Bertino, Weimin Sun, Charles M. Strom, Noh Jin Park
  • BCR-ABL1 SPLICE VARIANTS AND USES THEREOF
    Publication number: 20170306410
    Abstract: The present invention is based on BCR-ABL1 splice variants which result from insertion and/or truncation of the bcr-abl1 transcript and the finding that these variants provide resistance to kinase domain inhibitors such as imatinib, nilotinib and dasatinib.
    Type: Application
    Filed: February 10, 2017
    Publication date: October 26, 2017
    Applicant: Quest Diagnostics Investments Incorporated
    Inventor: Wanlong Ma
  • Kits for detecting /intracellulare nucleic acid
    Patent number: 9797018
    Abstract: Disclosed is a method for determining the presence of Mycobacterium avium complex nucleic acids in a biological sample. In particular, the mig gene of M. avium and the DT1 gene of M. intracellulare are detected, preferably following amplification. In addition, the method distinguishes between species of M. avium and M. intracellulare. Also described are oligonucleotides that can be used as primers to amplify target genes such as mig and DT1 genes and as probes as well as kits containing the oligonucleotide.
    Type: Grant
    Filed: November 14, 2011
    Date of Patent: October 24, 2017
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Edgar Ong, Maurice Exner
  • Lipoprotein analysis by differential charged-particle mobility
    Patent number: 9791464
    Abstract: The invention provides methods of preparation of lipoproteins from a biological sample, including HDL, LDL, Lp(a), IDL, and VLDL, for diagnostic purposes utilizing differential charged particle mobility analysis methods. Further provided are methods for analyzing the size distribution of lipoproteins by differential charged particle mobility, which lipoproteins are prepared by methods of the invention. Further provided are methods for assessing lipid-related health risk, cardiovascular condition, risk of cardiovascular disease, and responsiveness to a therapeutic intervention, which methods utilize lipoprotein size distributions determined by methods of the invention.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: October 17, 2017
    Assignee: QUEST DIAGNOSTICS INVESTMENTS INCORPORATED
    Inventors: Michael P. Caulfield, Richard E Reitz, Shuguang Li, Gloria Kwangja Lee, Ronald Krauss, Patricia J. Blanche, W. Henry Benner, Earl Cornell
  • DEVICE AND METHOD FOR EVALUATING AMOUNT OF BIOLOGICAL SAMPLE IN A SPECIMEN CONTAINER
    Publication number: 20170292868
    Abstract: An apparatus and method are provided to evaluate an amount of a biological sample in a specimen container. A fixture has a bottom surface configured to support a specimen container. A reference indicator is disposed at a predetermined height relative to the bottom surface. The reference indicator is configured to facilitate a visual comparison of the reference indicator with a height of a volume of a biological sample in the specimen container.
    Type: Application
    Filed: September 16, 2015
    Publication date: October 12, 2017
    Applicant: Quest Diagnostics Investments Incorporated
    Inventors: Christine AMENDT, Sevag BEDROSIAN, Gordon LOVE, Mkrtich DANIYELYAN, Miguel TORRERO
  • Nucleic acid detection combining amplification with fragmentation
    Patent number: 9783854
    Abstract: Provided herein are methods and compositions for detection of a nucleic acid target in a sample. The methods and compositions use primer directed amplification in conjunction with nucleic acid fragmentation. The methods have high sensitivity even in the presence of a large amount of non-target nucleic acid. Also provided are oligonucleotides and kits useful in the method. Exemplary nucleic acid targets are those with mutant gene sequence such as mutant sequence of the EGFR, APC, TMPRSS2, ERG and ETV1 genes.
    Type: Grant
    Filed: April 6, 2015
    Date of Patent: October 10, 2017
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Heather R. Sanders, Kevin Z. Qu, Charles M. Strom, Richard A. Bender
  • NUCLEIC ACID ANALYSIS USING EMULSION PCR
    Publication number: 20170275693
    Abstract: The present invention provides methods for analyzing large nucleic acids including chromosomes and chromosomal fragments. In one aspect, the present invention provides a method of nucleic acid analysis comprising the steps of (a) obtaining a sample of nucleic acid comprising at least one chromosome or fragment greater than about 1 000 base pairs in length and containing a target region; (b) creating an emulsion in which each drop of the emulsion contains an average of between about 0-2, 0-1.75, 0-1.5, 0-1.0, 0-0.75, 0-0.5, or fewer chromosomes or fragments of step (a), (c) performing emulsion PCR, (d) quantifying the number of emulsion droplets containing amplified nucleic acid from the target region; (e) calculating the ratio of droplets containing amplified nucleic acid from the target region to total droplets; and (f) comparing the ratio of step (e) to a reference ratio representing a known genotype.
    Type: Application
    Filed: March 10, 2017
    Publication date: September 28, 2017
    Applicant: Quest Diagnostics Investments Incorporated
    Inventor: Charles M. Strom
  • DDR2 MUTATIONS AS TARGETABLE FEATURES OF MELANOMA OR BASAL CELL CARCINOMA
    Publication number: 20170260591
    Abstract: Described herein are methods for diagnosing melanoma or basal cell carcinoma based on mutations in the DDR2 gene. Further, a distinct subgroup of BRAF-mutated melanomas have somatic mutations in the DDR2 gene as well. Applications of this finding to routine diagnostics include the molecular stratification of melanoma, and the tissue identification of targetable DDR2 kinase mutations in routine formalin-fixed paraffin-embedded sections. Described herein are methods, compositions and kits related to the discovery that DDR2 mutations may be markers for melanoma generally, and BRAF-mediated melanoma in particular, opening up the possibility of dual therapy for melanoma by targeting both DDR2 and BRAF.
    Type: Application
    Filed: March 10, 2017
    Publication date: September 14, 2017
    Applicant: QUEST DIAGNOSTICS INVESTMENTS INCORPORATED
    Inventors: Daniel M. Jones, Yongbao Wang, Shere Billouin-Frazier, Justin Windham
  • Automated delivery of alerts with confirmation of receipt
    Patent number: 9749394
    Abstract: Systems and methods are provided for delivering information as alerts. Alerts may be sent to one or more destinations at one or more times, with possible destinations including, e.g., one or more dedicated software clients, portable wireless devices, and/or email accounts, among many other possibilities. The sender may receive confirmation of, and/or may keep persistent records of, among several possibilities, transmission of one or more of the alerts, receipt of one or more of the alerts by devices at their respective destinations, and/or presentation of the alert to the intended recipient. According to an embodiment of the invention, an alert may be used to delivery medical information, which may include an urgent result of a medical test that has been performed on a patient.
    Type: Grant
    Filed: December 30, 2008
    Date of Patent: August 29, 2017
    Assignee: QUEST DIAGNOSTICS INVESTMENTS INCORPORATED
    Inventors: Kamal Syal, David Evans
  • MPL mutations in JAK2 V617F negative patients with myeloproliferative disease
    Patent number: 9733249
    Abstract: The invention provides compositions and methods for diagnosing a patient as having a myeloproliferative disease by identifying mutations in the MPL gene or gene products.
    Type: Grant
    Filed: September 22, 2014
    Date of Patent: August 15, 2017
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Wanlong Ma, Maher Albitar
  • BCR-ABL variants
    Patent number: 9702877
    Abstract: A splice variant of bcr-abl mRNA that produces BCR-ABL protein with a truncated C-terminus and its role in resistance to treatment with kinase inhibitors is disclosed. Vectors for expressing the truncated gene product are provided as well as recombinant cells that express the truncated gene product from a cDNA construct. Also provided are methods compositions and kits for detecting the BCR-ABL splice variant. Additionally, methods for screening BCR-ABL kinase domain inhibitors which rely on the recombinant cells and methods of predicting likelihood for resistance of a CML patient with a BCR/ABL translocation respond to treatment with one or more BCR-ABL kinase inhibitors are also disclosed.
    Type: Grant
    Filed: May 26, 2009
    Date of Patent: July 11, 2017
    Assignee: QUEST DIAGNOSTICS INVESTMENTS INCORPORATED
    Inventor: Maher Albitar
  • METHOD FOR DIRECT MICROBIAL IDENTIFICATION
    Publication number: 20170191116
    Abstract: Described herein are methods for direct detection of microbial agent(s) in a polymicrobial sample, such as a biological sample from a human, without culturing the microbial agent(s). The direct detection can identify mixtures of bacteria and/or fungi in the sample. Also described are primer sequences and amplification techniques for performing the direct detection methods.
    Type: Application
    Filed: June 4, 2015
    Publication date: July 6, 2017
    Applicant: Quest Diagnostics Investments Incorporated
    Inventors: Erik P. Johnson, Nik Isely, Jamie L. Platt, Martin Siaw, Ron M. Kagen, Dale A. Schwab
  • METHYLATED MARKERS FOR COLORECTAL CANCER
    Publication number: 20170191135
    Abstract: Disclosed herein is a combination of genomic sequences whose methylation patterns have utility for the improved detection and differentiation between colorectal neoplasms. Further disclosed herein are methods, nucleic acids and kits for detecting or differentiating between colorectal neoplasms.
    Type: Application
    Filed: June 3, 2015
    Publication date: July 6, 2017
    Applicants: Quest Diagnostics Investments Incorporated, CLINICAL GENOMICS PTY LTD
    Inventors: Susanne Pedersen, Lawrence LaPointe, Rohan Baker, Amber C. Donahue, Yen-lin Peng, Frederic Waldman
  • Mass spectrometric determination of eicosapentaenoic acid and docosahexaenoic acid
    Patent number: 9696325
    Abstract: The invention relates to the detection of DHA and EPA. In a particular aspect, the invention relates to methods for detecting DHA and EPA by mass spectrometry and kits for carrying out such methods.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: July 4, 2017
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Scott M. Goldman, Julie A. Neidich
  • DISCRIMINATING BRAF MUTATIONS
    Publication number: 20170175198
    Abstract: Provided herein are methods for detecting and discriminating BRAF V600 mutations. Also provided herein are methods for diagnosis, prognosis, management, and treatment decisions of BRAF V600 mutation-related diseases or conditions.
    Type: Application
    Filed: February 20, 2015
    Publication date: June 22, 2017
    Applicant: Quest Diagnostics Investments Incorporated
    Inventors: Amber C. Donahue, Yen-lin Peng
  • Methods for detecting reverse triiodothyronine by mass spectrometry
    Patent number: 9685311
    Abstract: Provided are methods for determining the amount of reverse T3 in a sample using mass spectrometry. The methods generally involve ionizing reverse T3 in a sample and detecting and quantifying the amount of the ion to determine the amount of reverse T3 in the sample.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: June 20, 2017
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: J. Fred Banks, Peter P. Chou, Noriya M. Matt
  • Visual presentation of multi-dimensional data sets
    Patent number: 9678635
    Abstract: Computer systems and methods may display multi-dimensional data sets in a dynamically-generated ocular view, which may show the relationship between data points in the different dimensions. For example, such a data set may include in one dimension results of one or more laboratory tests and, in another dimension, body systems or functions that the respective tests may relate to. The ocular view may depict the relationships between the tests and the systems. By being generated dynamically, moreover, the ocular view may be able to present this information for arbitrary sets of test results, without a template having been generated in advance to specify the layout of some particular combination of results.
    Type: Grant
    Filed: December 31, 2012
    Date of Patent: June 13, 2017
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Peter Wilkinson, Kerry O'Brien